DE60219761D1 - Verwendung von quetiapin für die behandlung von kokain-abhängigkeit - Google Patents
Verwendung von quetiapin für die behandlung von kokain-abhängigkeitInfo
- Publication number
- DE60219761D1 DE60219761D1 DE60219761T DE60219761T DE60219761D1 DE 60219761 D1 DE60219761 D1 DE 60219761D1 DE 60219761 T DE60219761 T DE 60219761T DE 60219761 T DE60219761 T DE 60219761T DE 60219761 D1 DE60219761 D1 DE 60219761D1
- Authority
- DE
- Germany
- Prior art keywords
- quetiapin
- treatment
- cocaine dependency
- cocaine
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 title 2
- 229960003920 cocaine Drugs 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960004431 quetiapine Drugs 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 201000006152 substance dependence Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26680801P | 2001-02-06 | 2001-02-06 | |
| US266808P | 2001-02-06 | ||
| PCT/SE2002/000214 WO2002062346A1 (en) | 2001-02-06 | 2002-02-05 | Method of treating substance abuse with quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60219761D1 true DE60219761D1 (de) | 2007-06-06 |
| DE60219761T2 DE60219761T2 (de) | 2008-01-17 |
Family
ID=23016078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60219761T Expired - Fee Related DE60219761T2 (de) | 2001-02-06 | 2002-02-05 | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7304047B2 (de) |
| EP (1) | EP1359919B1 (de) |
| JP (1) | JP2004518699A (de) |
| AT (1) | ATE360425T1 (de) |
| DE (1) | DE60219761T2 (de) |
| ES (1) | ES2284830T3 (de) |
| WO (1) | WO2002062346A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| WO2006073360A1 (en) * | 2005-01-07 | 2006-07-13 | Astrazeneca Ab | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| WO2008052354A1 (en) * | 2006-11-03 | 2008-05-08 | University Of Saskatchewan | Method of treating demyelination diseases |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
| US11545173B2 (en) * | 2018-08-31 | 2023-01-03 | The Regents Of The University Of Michigan | Automatic speech-based longitudinal emotion and mood recognition for mental health treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| TW587938B (en) | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| WO2000071106A2 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treating weight gain |
-
2002
- 2002-02-05 US US10/470,368 patent/US7304047B2/en not_active Expired - Fee Related
- 2002-02-05 JP JP2002562353A patent/JP2004518699A/ja active Pending
- 2002-02-05 WO PCT/SE2002/000214 patent/WO2002062346A1/en active IP Right Grant
- 2002-02-05 DE DE60219761T patent/DE60219761T2/de not_active Expired - Fee Related
- 2002-02-05 EP EP02710643A patent/EP1359919B1/de not_active Expired - Lifetime
- 2002-02-05 AT AT02710643T patent/ATE360425T1/de not_active IP Right Cessation
- 2002-02-05 ES ES02710643T patent/ES2284830T3/es not_active Expired - Lifetime
-
2007
- 2007-07-06 US US11/774,213 patent/US20070249582A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7304047B2 (en) | 2007-12-04 |
| EP1359919B1 (de) | 2007-04-25 |
| JP2004518699A (ja) | 2004-06-24 |
| ES2284830T3 (es) | 2007-11-16 |
| ATE360425T1 (de) | 2007-05-15 |
| WO2002062346A1 (en) | 2002-08-15 |
| EP1359919A1 (de) | 2003-11-12 |
| US20040058910A1 (en) | 2004-03-25 |
| DE60219761T2 (de) | 2008-01-17 |
| HK1059391A1 (en) | 2004-07-02 |
| US20070249582A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60142590D1 (de) | Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen | |
| DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| DE60335997D1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
| ATE318820T1 (de) | Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren. | |
| DE60228713D1 (de) | Zusammensetzungen für die behandlung von haaren und/oder kopfhaut | |
| DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| DE50214540D1 (de) | Stanz bei der behandlung von wunden | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| DE60223688D1 (de) | Verfahren zur behandlung von multiplem myelom | |
| DE60327074D1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
| DE69943089D1 (de) | Methode zur behandlung von staphylokokkeninfektionen | |
| DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60219761D1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
| DE60115647D1 (de) | Verbindungen zur behandlung von beeinträchtigten fundischen entspannung | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| DE69827387D1 (de) | Verwendung von pramipexol zur behandlung von restless-legs-syndrom | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE287713T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE483848T1 (de) | Verfahren zur behandlung von cellulosischen formkörpern | |
| ATE334174T1 (de) | System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |